Johnson & Johnson Gets FDA Priority Review of Nipocalimab
No. 2 South Carolina takes on Texas A&M
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback